5-(2-fluorophenyl)-1,3-dihydro-7-iodo-2H-1,4-benzodiazepin-2-one | 30843-56-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 5-(2-fluorophenyl)-1,3-dihydro-7-iodo-2H-1,4-benzodiazepin-2-one
• 英文别名: 1,3-dihydro-5-(2-fluorophenyl)-7-iodo-2H-1,4-benzodiazepin-2-one；5-(2-fluoro-phenyl)-7-iodo-1,3-dihydro-benzo[e][1,4]diazepin-2-one；1,3-dihydro-5-(2-fluoro phenyl)-7-iodo-1,4-benzodiazepin-2(2H)-one；7-iodo-1,3-dihydro-5-(2-fluorophenyl)-2H-1,4-benzodiazepine-2-one；1,3-Dihydro-5-(2-fluorphenyl)-7-iod-2H-1,4-benzodiazepin-2-on；2H-1,4-Benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-7-iodo-；5-(2-fluorophenyl)-7-iodo-1,3-dihydro-1,4-benzodiazepin-2-one
• CAS: 30843-56-2
• 化学式: C₁₅H₁₀FIN₂O
• 分子量: 380.16
• InChiKey: UBSKLVILVGEEON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(2-fluorophenyl)-1,3-dihydro-7-iodo-2H-1,4-benzodiazepin-2-one 在 氯化亚砜 、 tetraphosphorus decasulfide 、 potassium tert-butylate 、 氧气 、 silica gel 、 碳酸氢钠 、 三乙胺 、 肼 、 亚磷酸三乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 二乙二醇二甲醚 、 异丙醇 、 甲苯 为溶剂， 反应 9.33h， 生成 rac-6-(2-fluorophenyl)-8-iodo-4-methoxy-1-methyl-4H-<1,2,4>triazolo<4,3-a><1,4>benzodiazepine
  参考文献：
  名称：

  Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor

  摘要：

  A series of [1,2,4]triazolo[4,3-alpha][1,4]benzodiazepines bearing an ethynyl functionality at the 8-position and the isosteric thieno[3,2-f][1,2,4]triazolo[4,3-alpha][1,4]diazepines were prepared and evaluated as antagonists of platelet activating factor. The effects of substitution were explored in in vitro and in vivo test systems designed to measured PAF-antagonistic activity. Results are discussed and compared with previously published data. Many of the compounds had activity superior to WEB 2086, compound 1. In general, the thieno analogues exhibited better oral activity than the corresponding benzodiazepines. The duration of activity upon oral administration was modulated by the substitution on the acetylenic side chain. Compounds 71 and 81 were selected for further pharmacological evaluation as a result of their good oral potency and exceptionally long duration of action.

  DOI：

  10.1021/jm00107a048
• 作为产物：
  描述：

  (2-amino-5-iodophenyl)(2-fluorophenyl)methanone 在 氨 、 sodium carbonate 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 17.0h， 生成 5-(2-fluorophenyl)-1,3-dihydro-7-iodo-2H-1,4-benzodiazepin-2-one
  参考文献：
  名称：

  Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor

  摘要：

  A series of [1,2,4]triazolo[4,3-alpha][1,4]benzodiazepines bearing an ethynyl functionality at the 8-position and the isosteric thieno[3,2-f][1,2,4]triazolo[4,3-alpha][1,4]diazepines were prepared and evaluated as antagonists of platelet activating factor. The effects of substitution were explored in in vitro and in vivo test systems designed to measured PAF-antagonistic activity. Results are discussed and compared with previously published data. Many of the compounds had activity superior to WEB 2086, compound 1. In general, the thieno analogues exhibited better oral activity than the corresponding benzodiazepines. The duration of activity upon oral administration was modulated by the substitution on the acetylenic side chain. Compounds 71 and 81 were selected for further pharmacological evaluation as a result of their good oral potency and exceptionally long duration of action.

  DOI：

  10.1021/jm00107a048

文献信息

• Triazolo(4,3-A)(1,4)benzodiazepines and thieno
  申请人：Hoffmann-La Roche Inc.

  公开号：US04959361A1

  公开（公告）日：1990-09-25

  The invention relates to compounds of the formula ##STR1## wherein X is --CH.dbd.CH-- or S; R.sub.1 is lower alkyl, lower alkoxy or trifluoromethyl; R.sub.2 is hydrogen, lower alkyl, lower alkoxy, hydroxy or alkanoyloxy; R.sub.3 and R.sub.4, independently, are hydrogen, chlorine, fluorine, lower alkyl or lower alkoxy; s is an integer from 0 to 1, provided that when s is 1, R.sub.2 cannot be hydroxy, lower alkoxy or alkanoyloxy; R.sub.5 is a radical of the formula R.sub.6 --(CH.sub.2).sub.n -- or R.sub.7 --O--(CH.sub.2).sub.m -- wherein R.sub.6 and R.sub.7 are aryl or a heterocyclic radical, n is an integer of from 0 to 2 and m is an integer of from 1 to 2, provided that, when n is 0, R.sub.6 must be attached through a carbon to carbon bond, and provided that R.sub.7 is always attached through a carbon to oxygen bond, and, when at least one asymmetric carbon is present, its enantiomers and racemates, and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characterized by excess platelet activating factor or for the prevention and treatment of cardiovascular diseases, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shock or transplant rejection.

  本发明涉及通式##STR1##的化合物，其中X为--CH=CH--或S；R1为低级烷基、低级烷氧基或三氟甲基；R2为氢、低级烷基、低级烷氧基、羟基或烷酰氧基；R3和R4各自独立地为氢、氯、氟、低级烷基或低级烷氧基；s为0至1的整数，但当s为1时，R2不能为羟基、低级烷氧基或烷酰氧基；R5为通式R6--(CH2)n--或R7--O--(CH2)m--的基团，其中R6和R7为芳基或杂环基团，n为0至2的整数，m为1至2的整数，但当n为0时，R6必须通过碳-碳键连接，且R7始终通过碳-氧键连接，当存在至少一个不对称碳时，包括其对映体和外消旋体，以及药学上可接受的酸加成盐。通式I的化合物表现出作为血小板活化因子（PAF）拮抗剂的活性，因此可用于治疗以过量血小板活化因子为特征的疾病状态，或用于预防和治疗心血管疾病、肺部疾病、免疫紊乱、炎症性疾病、皮肤病、休克或移植排斥反应。
• Imidazodiazepines and processes therefor
  申请人：Hoffmann-La Roche Inc.

  公开号：US04280957A1

  公开（公告）日：1981-07-28

  Novel Imidazobenzodiazepines and their analogs are useful as anticonvulsants, muscle relaxant, anxiolytic and sedative agents. Preferred compounds of this class belong to the imidazo[1,5-a][1,4]diazepine series which may have a very wide variety of organic substituents. An especially preferred genus included within the purview of the invention encompasses a compound of the formula ##STR1## wherein R.sub.1 is hydrogen and lower alkyl preferably methyl; R.sub.3 and R.sub.5 are hydrogen; R.sub.4 is hydrogen, nitro and halogen, most preferably, chlorine, and in a most preferred embodiment when positioned on the fused benzo portion of the imidazobenzodiazepine is in the 8-position thereof, R.sub.6 is phenyl or halo, nitro, or lower alkyl-substituted phenyl, preferably, halo, with fluorine being the preferred halogen, the substituted fluoro being positioned in the 2-position of the phenyl moiety and R.sub.2 is hydrogen and lower alkyl.

  新型咪唑苯二氮杂环己烯和它们的类似物可用作抗癫痫药、肌肉松弛剂、抗焦虑药和镇静剂。该类的优选化合物属于咪唑并[1,5-a][1,4]二氮杂环己烯系列，可能具有非常广泛的有机取代基。在本发明的范围内尤其优选的一类包括式中的化合物，其中 R.sub.1 为氢和较低的烷基，最好是甲基；R.sub.3 和 R.sub.5 为氢；R.sub.4 为氢、硝基和卤素，最好是氯，在最优选的实施方式中，当位于咪唑苯二氮杂环的融合苯部位的 8-位时，R.sub.6 为苯基或卤素、硝基或较低烷基取代的苯基，最好是卤素，取代的氟在苯基中的 2-位，R.sub.2 为氢和较低的烷基。
• Synthesis of imidazo[1,5-a]diazepine-3-carboxylates
  申请人：Hoffmann-La Roche Inc.

  公开号：US04118386A1

  公开（公告）日：1978-10-03

  A process to produce diazepine-3-carboxylates of the formula ##STR1## is selected from the group consisting of ##STR2## R.sub.6 is selected from the group consisting of hydrogen, halogen, nitro, cyano, trifluoromethyl, lower alkyl, and lower alkanoyl; R.sub.4 is lower alkyl; R.sub.3 is selected from the group consisting of phenyl, mono-substituted phenyl, disubstituted phenyl, pyridyl and mono-substituted pyridyl; and R.sub.2 is hydrogen or lower alkyl which comprises reacting a compound of the formula ##STR3## wherein R.sub.1 is of the formula ##STR4## AND R.sub.5 is lower alkyl with a compound of the formula N.dbd.C-CH.sub.2 --COOR.sub.4 in the presence of a base sufficiently strong to generate the anion of the isocyanoacetate.

  选取一种生产式为##STR1##的二氮杂环己酸酯的方法，所述方法选自下列组合之一：##STR2##其中R.sub.6选自氢、卤素、硝基、氰基、三氟甲基、低烷基和低烷酰基；R.sub.4为低烷基；R.sub.3选自苯基、单取代苯基、双取代苯基、吡啶基和单取代吡啶基；R.sub.2为氢或低烷基，包括以下步骤：将式为##STR3##的化合物（其中R.sub.1为式##STR4##，R.sub.5为低烷基）与式为N.dbd.C-CH.sub.2 --COOR.sub.4的化合物在足够强的碱存在下反应，以生成异氰乙酸酯的负离子。
• Intermediates for tricyclic benzodiazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US03965151A1

  公开（公告）日：1976-06-22

  Tricyclic benzodiazepine derivatives ("A") bearing a hydroxylower alkyl substituent in the 1-position and a heterocyclic ring joined between positions 4 and 5 of the benzodiazepine moiety are described. The heterocyclic ring will contain the nitrogen atom appearing at position 4 of the benzodiazepine ring as well as the hetero atom, which may be either oxygen or nitrogen, attached to the carbon atom at the 5-position of the benzodiazepine ring. "A" bearing an oxygen atom in the new heterocyclic ring may be formed from the corresponding 4,5-unsaturated benzodiazepines by treatment with an epoxide compound in the presence of an acid catalyst. "A" bearing either a nitrogen or an oxygen atom in the new heterocyclic ring may be prepared by cyclization of the corresponding open compound. "A" are useful as sedative, muscle relaxant and anti-convulsant agents.

  描述了在三环苯二氮卓衍生物（“A”）中，1位位置带有一个氢氧基较低的烷基取代基，以及在苯二氮卓基团的4位和5位之间连接的杂环环。该杂环环将包含出现在苯二氮卓环的4位的氮原子，以及连接到苯二氮卓环5位的碳原子上的杂原子，该杂原子可能是氧或氮。“A”中带有新杂环环中的氧原子可以通过在酸催化剂存在下用环氧化合物处理相应的4,5-不饱和苯二氮卓制备而成。“A”中带有新杂环环中的氮或氧原子可以通过对应开放化合物的环化制备而成。“A”可用作镇静剂、肌肉松弛剂和抗惊厥剂。
• 1-Polyhydroxy alkyl-1,4-benzodiazepin-2-ones
  申请人：Hoffmann-La Roche Inc.

  公开号：US03963777A1

  公开（公告）日：1976-06-15

  Novel 1,4-benzodiazepin-2-ones bearing a polyhydroxyalkyl group in the 1-position are disclosed. These 1-substituted benzodiazepins are useful as muscle relaxant, anti-convulsant and sedative agents.

  揭示了在1-位置带有多羟基烷基基团的新型1,4-苯二氮杂环己酮。这些1-取代苯二氮杂环己酮可用作肌肉松弛剂、抗惊厥剂和镇静剂。